Core Points - Rosen Law Firm is reminding KBR, Inc. investors of the November 18, 2025 deadline to join a securities class action lawsuit related to the company's performance during the Class Period from May 6, 2025, to June 19, 2025 [1][2][5] - The lawsuit alleges that KBR made materially false and misleading statements regarding its partnership with the U.S. Department of Defense's Transportation Command, which affected investor decisions and caused damages when the truth was revealed [5] Class Action Details - Investors who purchased KBR securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors must act before the November 18, 2025 deadline to serve as lead plaintiff, representing other class members [3][6] Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - Rosen Law Firm is urging investors of RCI Hospitality Holdings, Inc. to secure legal counsel before the November 20, 2025 deadline for a securities class action lawsuit related to alleged misconduct during the Class Period from December 15, 2021, to September 16, 2025 [1][5]. Group 1: Legal Action Details - Investors who purchased RCI Hospitality securities during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by November 20, 2025 [3]. - The lawsuit alleges that defendants made materially false statements and failed to disclose significant issues, including tax fraud and bribery, which misrepresented the legal risks and business prospects of RCI Hospitality [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Molina - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and prospects were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Fluor Corporation to secure legal counsel before the November 14, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from February 18, 2025, to July 31, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Fluor securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by November 14, 2025 [3]. - The lawsuit alleges that Fluor made false and misleading statements regarding project costs and financial guidance, which negatively impacted the company's business and financial results [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions, highlighting its own success in achieving significant settlements for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and recovering over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is urging investors of Cytokinetics, Inc. to take action before the November 17, 2025 deadline related to a securities class action lawsuit concerning misleading statements about the company's New Drug Application for aficamten [2][6]. Group 1: Class Action Details - The class period for the lawsuit is from December 27, 2023, to May 6, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the NDA submission and approval process for aficamten, specifically regarding expected FDA approval in the second half of 2025 [6]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [5]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5].

Core Insights - Ravelin Properties REIT reported its highest quarterly gross rental revenue and net operating income since Q3 2024, indicating a return to stability in same-property net operating income for the first time since Q2 2024 [3][4] - The REIT signed 235,163 square feet of new leases and renewals in Q3 2025 at a weighted average net rental rate of $18.29 per square foot, which is 20.5% above prior rental rates for previously vacant spaces [4] - The current leasing pipeline exceeds 895,000 square feet, with over 100,000 square feet of rent reviews underway in Ireland, presenting opportunities to increase in-place rents [4] Financial Performance - For the three months ended September 30, 2025, rental revenue was $47.5 million, a decrease of 5.2% from $50.2 million in the same period of 2024 [6] - Net operating income (NOI) for Q3 2025 was $21.3 million, down 12.2% from $24.3 million in Q3 2024 [6] - The REIT reported a net loss of $17.4 million for Q3 2025, a significant improvement compared to a net loss of $182.1 million in Q3 2024 [6] Occupancy and Property Management - As of September 30, 2025, portfolio occupancy was 74.5%, down from 75.8% as of June 30, 2025, primarily due to a known vacancy at 280 Broadway in Winnipeg [4] - Management is considering redeveloping high-vacancy properties, including a potential conversion of 280 Broadway into a self-storage facility [4] Liquidity and Debt Metrics - The REIT's liquidity as of September 30, 2025, included unrestricted cash of $12.2 million, a decrease from $13.6 million at the end of 2024 [4] - The net debt to adjusted EBITDA ratio was reported at 14.5x, up from 12.9x at the end of 2024, indicating increased leverage [6][21] - Adjusted EBITDA for the trailing twelve months was $76.4 million, down from $89.4 million in the previous year [19][21] Future Outlook - The REIT is in discussions with senior lenders to extend forbearance agreements that expired on September 30, 2025, with no agreement reached as of the report date [5] - The acquisition of a 25% co-ownership interest in two GTA properties is expected to further reduce the net debt to adjusted EBITDA ratio in upcoming quarters [4]

Core Viewpoint - Rosen Law Firm is reminding investors of Jasper Therapeutics, Inc. about the upcoming lead plaintiff deadline for a securities class action lawsuit, which is set for November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the November 18, 2025 deadline [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and procedures, which could negatively impact the regulatory and commercial prospects of its products, particularly briquilimab [5]. - The claims suggest that the company's public statements were materially false and misleading, leading to investor damages when the true details became known [5].

Core Viewpoint - Gold Springs Resource Corp. has released its unaudited consolidated financial statements for the three and nine months ended September 30, 2025, indicating a focus on exploration and resource expansion in the gold and silver sectors [1]. Financial Performance - For the nine months ended September 30, 2025, general and administrative expenses decreased to $0.41 million from $0.42 million in the same period of 2024 [2]. - In the three months ended September 30, 2025, general and administrative expenses rose to $0.14 million compared to $0.11 million in the same quarter of 2024 [2]. - Exploration spending increased to $0.77 million during the nine months ended September 30, 2025, up from $0.45 million in the prior year, primarily due to drilling activities [2]. - The company reported a net loss of $0.48 million for the nine months ended September 30, 2025, compared to a net loss of $0.52 million in the same period of 2024 [2]. - For the three months ended September 30, 2025, the net loss remained stable at $0.18 million, the same as the previous year [2]. - As of September 30, 2025, the company had cash reserves of $0.01 million [2]. Company Overview - Gold Springs Resource Corp. is focused on the exploration and expansion of gold and silver resources at its Gold Springs project, located on the border of Nevada and Utah, USA [3]. - The Gold Springs project is situated in the Great Basin, recognized as one of the best mining jurisdictions globally [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranked in the top 4 for settlements since 2013, recovering hundreds of millions for investors [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of Quanex Building Products Corporation to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from December 12, 2024, to September 5, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Quanex securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by November 18, 2025 [3]. - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance, which were significantly underinvested, leading to degraded conditions and potential significant costs [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including the largest settlement against a Chinese company and recovering hundreds of millions for investors [4].